Exocrine Pancreatic Insufficiency Global Market Report 2024

The exocrine pancreatic insufficiency market size has grown strongly in recent years. It will grow from $2.41 billion in 2023 to $2.59 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The growth observed in the historical period can be attributed to several factors, including increased awareness and diagnosis of exocrine pancreatic insufficiency (EPI), a growing prevalence of digestive disorders, an aging population, and the associated decline in pancreatic function, as well as a rise in gastrointestinal surgeries. These factors collectively contribute to the increased recognition and incidence of exocrine pancreatic insufficiency during the historic period.

The exocrine pancreatic insufficiency market size is expected to see strong growth in the next few years. It will grow to $3.34 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The anticipated growth in the forecast period can be attributed to several factors, including a continued increase in awareness and screening for exocrine pancreatic insufficiency (EPI), an expanding geriatric population, a rising incidence of chronic diseases, improvements in patient access to healthcare services, and ongoing research and development in the field of digestive health. Major trends expected in the forecast period encompass the adoption of telehealth and digital health solutions, collaborative research initiatives, a focus on pediatric EPI, regulatory advances and fast-track designations, market expansion in emerging economies, and advancements in healthcare infrastructure. These trends collectively contribute to the projected growth and development in the management and understanding of exocrine pancreatic insufficiency.

The anticipated surge in chronic diseases is poised to be a driving force behind the expansion of the exocrine pancreatic insufficiency market in the coming years. Chronic diseases encompass enduring medical conditions that persist over an extended period, often exceeding three months. Prolonged occurrences of these diseases elevate the risk of secondary complications such as exocrine pancreatic insufficiency, prompting the need for enhanced management through medical interventions and therapies. Consequently, these interventions contribute to potentially prolonged lifespans for individuals dealing with such conditions. For example, a report published by the National Library of Medicine in January 2023 highlighted a projected 99.5% increase in individuals aged 50 years and above, affected by one or more chronic illnesses, expected to reach 142.66 million by 2050 in the United States, up from 71.522 million in 2020. Therefore, the surge in chronic diseases is anticipated to drive the exocrine pancreatic insufficiency market's growth.

The escalating cases of diabetes are expected to fuel the growth of the exocrine pancreatic insufficiency market. Diabetes, a chronic health condition characterized by inadequate insulin production or utilization by the body, leads to an accumulation of excessive blood sugar in the bloodstream. Pancreatic enzyme replacement treatment (PERT) becomes essential to supply adequate digestive enzymes for exocrine pancreatic insufficiency (EPI) and maintain the body's insulin levels. For instance, a report from the Institute for Health Metrics and Evaluation in June 2023 projected global diabetes cases to reach 1.3 billion by 2050, up from 529 million in 2022. Therefore, the increasing prevalence of diabetes is expected to drive the growth of the exocrine pancreatic insufficiency market.

Escalating medical expenses stand as a primary restraint for the exocrine pancreatic insufficiency (EPI) market in the foreseeable future. The rising costs within the EPI market can limit patient access to crucial medications and treatments, potentially leading to delayed or suboptimal care, thus negatively impacting patient outcomes. Additionally, healthcare providers and payers grappling with budget constraints due to escalating medical expenses might encounter challenges in maintaining availability and reimbursement of EPI treatments. This difficulty may hinder the approval and widespread adoption of innovative therapies. For instance, a report from the American Hospital Association in April 2023 indicated that 84% of hospitals experienced increased costs due to adherence to insurer policies. Drug expenses per patient saw a 36.9% growth, while non-labor expenses increased from 8.2% in January 2019 to approximately 10.6% in January 2022. Therefore, rising medical costs are anticipated to impede the growth of the exocrine pancreatic insufficiency market in the forecast period.

Leading companies within the exocrine pancreatic insufficiency (EPI) market are prioritizing the establishment of patient advocacy groups to drive patient-centric product development. These advocacy groups in the realm of EPI are dedicated organizations focused on supporting and advocating for individuals affected by exocrine pancreatic insufficiency, empowering them to access information about their condition and available treatment options. For instance, in November 2021, Aimmune Therapeutics, Inc., a US-based biopharmaceutical firm specializing in EPI and chronic pancreatitis treatment, collaborated with Mission Cure, a nonprofit organization in the US dedicated to EPI treatment. Together, they launched an online patient community on the HealthUnlocked network, providing vital support and information to pancreatitis patients, including those dealing with exocrine pancreatic insufficiency (EPI). This platform serves as a space for patients to connect, share experiences, and receive support in managing chronic pancreatitis and related conditions.

In September 2021, AzurRx BioPharma Inc., a US-based pharmaceutical company, completed the acquisition of First Wave Bio Inc. for $229 million. This strategic acquisition enabled AzurRx to broaden its range of therapies for gastrointestinal illnesses and leverage the expertise of First Wave Bio in drug research and formulation. Additionally, this acquisition bolstered AzurRx's position in the market by offering a more extensive array of solutions addressing unmet medical needs, particularly in gastrointestinal conditions such as exocrine pancreatic insufficiency (EPI). First Wave Bio Inc., also based in the United States, specializes in developing medications for gastrointestinal disorders, including EPI.

Major companies operating in the exocrine pancreatic insufficiency market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, Medtronic plc, Eli Lilly and Company, Gilead Sciences Inc., Nestle Health Science S.A., Allergan plc, Chiesi Farmaceutici S.p.A., Wockhardt Ltd., Amryt Pharma Plc, Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, Aimmune Therapeutics Inc, Digestive Care Inc., Enzymedica Inc., Vivus Inc., Alcresta Therapeutics Inc., Cilian AG, Perseo Pharma AG, Enzyme Development Corporation, First Wave BioPharma Inc., Synspira Therapeutics.

North America was the largest region in the exocrine pancreatic insufficiency market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the exocrine pancreatic insufficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the exocrine pancreatic insufficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The exocrine pancreatic insufficiency market consists of revenues earned by entities by providing enzyme replacement therapy, nutritional counseling, monitoring, managing underlying conditions, lifestyle modifications, and gastroenterology consultation. The market value includes the value of related goods sold by the service provider or included within the service offering. The exocrine pancreatic insufficiency market also includes sales of Creon, zenpep, pancreaze, ultresa, and viokace. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The primary types of treatments for exocrine pancreatic insufficiency include nutritional management, pancreatic enzyme replacement therapy (PERT), and other interventions. Nutritional management involves planning and implementing dietary strategies to optimize an individual's nutritional status, supporting overall health and well-being. This approach is essential in the comprehensive care of individuals with exocrine pancreatic insufficiency (EPI), diagnosed through imaging tests such as Computed Tomography (CT) Scan, Abdominal Ultrasound, Secretin Pancreatic Function Test, Fecal Fat Test, Fecal Elastase Test (FE-1), and others. These diagnostic tests help identify symptoms such as abdominal pain, constipation, diarrhea, fatty stool, and weight loss. The drugs used for treating exocrine pancreatic insufficiency are distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and other outlets. These medications are utilized by end users such as hospitals, specialty clinics, and individuals receiving care at home.

The exocrine pancreatic insufficiency market research report is one of a series of new reports that provides exocrine pancreatic insufficiency market statistics, including exocrine pancreatic insufficiency industry global market size, regional shares, competitors with a exocrine pancreatic insufficiency market share, detailed exocrine pancreatic insufficiency market segments, market trends and opportunities, and any further data you may need to thrive in the exocrine pancreatic insufficiency industry. This exocrine pancreatic insufficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future- scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.